Juvmo was designed to offer a reduction in motor symptoms, while reducing non-motor side effects, through its more selective ...

This post is the first in a five-part series summarizing APDA’s recent “Ask the Expert” event on Smart Patients. During the ...

Michael J. Fox has spent decades navigating Parkinson’s disease while continuing to shape the conversations about the ...

Since its inception in 2000, The Michael J. Fox Foundation has become the world’s largest nonprofit funder of Parkinson’s research, recently marking over $3 billion in total contributions toward ...

Today's FDA approval of tavapadon makes it the first selective D1/D5 receptor agonist for the treatment of adults with Parkinson's disease.

A small study found disease-related odor compounds may show up in skin samples, including from the navel, but much larger trials are needed.

JUVMO™ is the first and only selective D1/D5 receptor agonist approved for adults with Parkinson's disease1 Taken once daily with or without levodopa therapy, JUVMO offers patients ...

Gain Therapeutics’ lead drug candidate rexaceract, formerly known as GT-02287, is in clinical development for the treatment ...

A new study by scientists at the CSIR-Centre for Cellular and Molecular Biology (CCMB) in Hyderabad has revealed how viral ...

Michael J. Fox has spent more than three decades turning one of the most difficult moments of his life into The Michael J. Fox’s Heartbreaking Parkinson’s Confession Leaves Emmys In Tears first appear ...

As part of its unwavering commitment to accelerate Parkinson's research, The Michael J. Fox Foundation for Parkinson's Research (MJFF) today announces All Grit. No Quit. — an ambitious multi-year $2.5 ...

“You can shrivel up and die ... or you can stand up and say, ‘I’m gonna live,’ Crews told Tamron Hall ...